Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative Online education and training Order products online Reimbursement resources Return a product Customer support

Call customer care

1 (888) 272-1001

EMBLEM™ MRI S-ICD System

Subcutaneous Implantable Defibrillator

   

ATLAS Randomized Controlled Trial: S-ICD Superior to TV-ICD1

Study overview

The ATLAS Trial is an investigator-sponsored research study (ISR) initiated, designed and led by Population Health Research Institute (PHRI), Jeff S. Healey MD, MSc, FHRS, and the ATLAS Steering Committee. It is the first prospective randomized controlled trial where the primary objective was to evaluate lead-related complication rates between the S-ICD and single chamber TV-ICD devices at six months after implant.

Hypothesis

The trial hypothesis is that S-ICD is superior to TV-ICD with respect to serious lead-related complications*, including:

  • Moderate-severe or severe tricuspid regurgitation
  • Hemothorax or pneumothorax
  • Cardiac perforation, tamponade, or pericardial effusion or pericarditis
  • Ipsilateral upper extremity deep vein thrombosis
  • Lead dislodgement or loss of sensing or pacing requiring revision

 

Sample Size and Timing

The trial randomized 503 patients, who passed electrocardiographic screening, from clinical centers across Canada between February 2017 and July 2021.

Enrollment and randomization protocol.
   

Primary Outcomes

Patients in the S-ICD group showed significantly fewer serious lead-related complications* than patients implanted with a single-chamber TV-ICD.

The ATLAS trial met its primary superiority endpoint demonstrating a highly significant 92% reduction in serious lead-related complications* at six months for the EMBLEM™ S-ICD compared to any manufacturers single chamber TV-ICD devices. p=0.0031
Serious lead-related complications, 92% down with S-ICD compared to TV-ICD.
Serious lead-related complication* occurred in 12 times as many patients in the single chamber TV-ICD arm (4.8%) at six months compared to 1 patient (0.4%) in the S-ICD arm.1
4.8% vs. 4% patients in S-ICD arm showed significantly fewer serious complications vs. patients with single-chamber TV-ICD.
   

Secondary Analysis: Effects of Implantable Cardioverter-Defibrillator Leads on the Tricuspid Valve and Right Ventricle: A Randomized Comparison of Transvenous versus Subcutaneous Leads.2

Data from a secondary analysis of the investigator-sponsored research ATLAS trial evaluated in nearly 450 patients the severity of Tricuspid Regurgitation (TR) at six months following the implantation of a transvenous implantable cardioverter-defibrillator (TV-ICD) versus the EMBLEM S-ICD.

At six months, patients in the TV-ICD group were seven times more likely to have worsening tricuspid regurgitation (p<0.001) than those in the S-ICD group. 2
6 months after implant, 7 times more patients in the TV-ICD group were likely to develop worsening tricuspid regurgitation.
Of those with worsening tricuspid regurgitation, moderate or severe TR developed in 6.9% of patients receiving a TV-ICD versus 2.3% of those receiving an S-ICD (p=0.02).2
3 times as many patients with a TV-ICD had moderate or severe tricuspid regurgitation.
Watch the presentation
 
Top